Nanobiotix News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

22.09.14	Nanobiotix Expands Operations into the USA as Part of Its International Development Strategy (Businesswire)
22.09.14	Nanobiotix Expands Operations into the USA as Part of Its International Development Strategy (Businesswire)
11.07.14	Nanobiotix revenue for the 2nd quarter of 2014 (Businesswire)
02.06.14	Nanobiotix presents successful Phase I results for its lead nanomedicine product NBTXR3 at ASCO (GlobeNewswire)
01.04.14	Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Businesswire)
31.01.14	Nanobiotix: 2013 Annual revenues (Businesswire)
16.01.14	Nanobiotix Strengthens Its Supervisory Board for the Next Stage of Its Development (Businesswire)
07.01.14	Nanobiotix 2013 Review: Significant Corporate and Clinical Progress (Businesswire)
12.11.13	NANOBIOTIX: Revenue for the 3rd quarter of 2013 (Businesswire)
23.09.13	Nanobiotix Strengthens Its Management Team (Businesswire)
12.07.13	Nanobiotix - Revenue for the Second Quarter of 2013 (Businesswire)
25.01.13	NANOBIOTIX: 2012 Revenues (Businesswire)
15.11.12	NANOBIOTIX: Revenue for the 3rd Quarter of 2012 (Businesswire)
13.11.12	Nanobiotix: Unabhängiges Datenüberwachungskomitee bestätigt gutes Sicherheitsprofil von NBTXR3 bei der ersten Patientengruppe mit fortgeschrittenem Weichteilsarkom für Phase I (Businesswire)
13.11.12	Nanobiotix: Phase I Independent Data Monitoring Committee Confirms Good Safety of NBTXR3 in the First Group of Patients with Advanced Soft Tissue Sarcoma (Businesswire)
13.11.12	Nanobiotix: Phase I Independent Data Monitoring Committee Confirms Good Safety of NBTXR3 in the First Group of Patients with Advanced Soft Tissue Sarcoma (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V